glucagon has been researched along with adamantane in 40 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (adamantane) | Trials (adamantane) | Recent Studies (post-2010) (adamantane) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 3,449 | 360 | 1,790 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (35.00) | 29.6817 |
| 2010's | 26 (65.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrén, B; Holmes, D; Jansson, PA; Landin-Olsson, M; Schweizer, A; Svensson, M | 1 |
| Erlich, R | 1 |
| Dunning, BE; Foley, JE; Mänttäri, S; Matikainen, N; Mills, D; Schweizer, A; Taskinen, MR; Ulvestad, A | 1 |
| Mikhail, N | 1 |
| Bullock, JM; Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Ligueros-Saylan, M; Wang, Y | 1 |
| Scheen, AJ | 1 |
| El-Ouaghlidi, A; Foley, J; Holmes, D; Holst, JJ; Nauck, MA; Rehring, E; Schweizer, A | 1 |
| Baron, MA; Deacon, CF; Foley, JE; Holst, JJ; Landin-Olsson, M; Rendell, M; Rochotte, E; Rosenstock, J | 1 |
| Ahrén, B | 1 |
| Deacon, CF; Dunning, BE; Foley, JE; He, YL; Holst, JJ; Kelley, DE; Leone-Jones, A; Ligueros-Saylan, M; Yu, T | 1 |
| Cherrington, AD; Duttaroy, A; Edgerton, DS; Hobbs, CH; Johnson, KM; Neal, DW; Scott, M; Zhang, X | 1 |
| Bock, G; Camilleri, M; Cobelli, C; Dalla Man, C; Foley, JE; Giesler, PD; Ligueros Saylan, M; Rizza, RA; Serra, DB; Toffolo, G; Vella, A | 1 |
| Ahrén, B; Dejager, S; Dunning, BE; Foley, JE; Nilsson, PM; Persson, M; Schweizer, A | 1 |
| Gallwitz, B; Thornberry, NA | 1 |
| Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B | 1 |
| Svec, F | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 4 |
| He, YL; Ito, H; Sekiguchi, K; Terao, S; Yamaguchi, M | 1 |
| Inaba, W; Kamata, K; Mizukami, H; Takahashi, K; Tsuboi, K; Yagihashi, S | 1 |
| Asahara, S; Bartolome, A; Etoh, H; Fuchita, M; Hashimoto, N; Hosooka, T; Inoue, H; Kanno, A; Kido, Y; Koyanagi-Kimura, M; Matsuda, T; Mieda, Y; Seino, S; Shimizu, S; Takahashi, H; Teruyama, K | 1 |
| Ahrén, B; Farngren, J; Foley, JE; Persson, M; Schweizer, A | 2 |
| Deacon, CF; Hartmann, B; Holst, JJ; Hovendal, C; Knop, FK; Meisner, S; Plamboeck, A; Svendsen, LB; Veedfald, S; Vilsbøll, T; Wettergren, A | 1 |
| Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 1 |
| Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M | 1 |
| Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Deacon, CF; Feinle-Bisset, C; Heruc, GA; Horowitz, M; Little, TJ; Luscombe-Marsh, N; Rayner, CK | 1 |
| Ahrén, B; Malmgren, S | 1 |
| George, PS; McCrimmon, RJ | 1 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| Jütte, H; Meier, J; Montanya, E; Nauck, M; Schmidt, W; Tannapfel, A; Ueberberg, S; Uhl, W | 1 |
| Kadowaki, T; Muto, S; Ouchi, Y; Seino, Y; Shimazaki, R | 1 |
| Abdelaziz, RR; Abdelhamid, AM; Salem, HAA | 1 |
| Eriksson, JW; Esterline, R; Johnsson, E; Kamble, PG; Katsogiannos, P; Langkilde, AM; Lundkvist, P; Pereira, MJ | 1 |
4 review(s) available for glucagon and adamantane
| Article | Year |
|---|---|
Exenatide: a novel approach for treatment of type 2 diabetes.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Humans; Hypoglycemic Agents; Insulin; Nitriles; Peptides; Pyrrolidines; Treatment Outcome; Venoms; Vildagliptin | 2006 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
23 trial(s) available for glucagon and adamantane
| Article | Year |
|---|---|
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Circadian Rhythm; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Enzyme Inhibitors; Female; Glucagon; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Pyrrolidines | 2004 |
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Topics: Adamantane; Apolipoprotein B-48; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Intestinal Mucosa; Intestines; Lipids; Lipoproteins; Male; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Time Factors; Treatment Outcome; Triglycerides; Vildagliptin | 2006 |
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Topics: Adamantane; Adult; Algorithms; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glyburide; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Topics: Adamantane; Blood Glucose; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Inulin; Kinetics; Male; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Vildagliptin | 2008 |
Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 1; Feeding Behavior; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Nitriles; Pyrrolidines; Vildagliptin | 2008 |
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Topics: Adamantane; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Digestion; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Nitriles; Placebos; Postprandial Period; Pyrrolidines; Satiety Response; Vildagliptin | 2009 |
Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Topics: Adamantane; Aged; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2010 |
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2010 |
Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin; Young Adult | 2012 |
Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty.
Topics: Acetaminophen; Adamantane; Aged; Area Under Curve; Case-Control Studies; Dipeptidyl-Peptidase IV Inhibitors; Duodenal Ulcer; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Insulin-Secreting Cells; Male; Nitriles; Pylorus; Pyrrolidines; Vagotomy, Truncal; Vildagliptin | 2013 |
Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2013 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Topics: Adamantane; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period | 2014 |
Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Food; Glucagon; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin | 2014 |
Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Topics: Adamantane; Adolescent; Adult; Appetite Regulation; Cross-Over Studies; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Energy Intake; Energy Metabolism; Food-Drug Interactions; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Nitriles; Peptide Fragments; Peptide YY; Postprandial Period; Pyrrolidines; Vildagliptin; Young Adult | 2014 |
Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia.
Topics: Adamantane; Adult; Blood Glucose Self-Monitoring; Cross-Over Studies; Diabetes Mellitus, Type 1; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Monitoring, Ambulatory; Norepinephrine | 2016 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
Topics: Adamantane; Aged; Blood Glucose; C-Peptide; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Placebo Effect; Treatment Outcome | 2017 |
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2019 |
13 other study(ies) available for glucagon and adamantane
| Article | Year |
|---|---|
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines | 2005 |
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Topics: Adamantane; Animals; Consciousness; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Glucagon; Glucagon-Like Peptide 1; Glucose; Insulin; Liver; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2009 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adamantane; Animals; Apoptosis; Cell Proliferation; Deoxyguanosine; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Nitriles; Pyrrolidines; Rats; Time Factors; Vildagliptin | 2012 |
DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
Topics: Adamantane; Animals; Blood Glucose; CCAAT-Enhancer-Binding Protein-beta; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Exenatide; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Hyperglycemia; Insulin; Insulin-Secreting Cells; Leupeptins; Mice; Mice, Transgenic; Nitriles; Peptides; Pyrrolidines; Venoms; Vildagliptin | 2012 |
DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.
Topics: Adamantane; Animals; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Hypoglycemia; Mice; Mice, Knockout; Nitriles; Pyrrolidines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Vildagliptin | 2015 |
Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.
Topics: Acinar Cells; Adamantane; Adenocarcinoma; Adult; Aged; Carcinoma in Situ; Case-Control Studies; Cystadenoma; Diabetes Mellitus, Type 2; Digestive System Surgical Procedures; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Secreting Cells; Humans; Incretins; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Middle Aged; Neuroendocrine Tumors; Nitriles; Organ Size; Pancreas; Pancreas, Exocrine; Pancreatic Neoplasms; Pancreatitis, Chronic; Peptides; Pyrrolidines; Sitagliptin Phosphate; Tissue Donors; Venoms; Vildagliptin | 2016 |
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glucagon; Glutathione; Glycated Hemoglobin; Insulin; Male; Malondialdehyde; Nitric Oxide; Nitriles; Pancreas; Pioglitazone; Pyrrolidines; Rats, Sprague-Dawley; Streptozocin; Superoxide Dismutase; Thiazolidinediones; Vildagliptin | 2018 |